Menu
Search
|

Menu

Close
X

Adamis Pharmaceuticals Corp ADMP.OQ (NASDAQ Stock Exchange Capital Market)

2.90 USD
+0.11 (+3.94%)
As of Oct 16
chart
Previous Close 2.79
Open 2.80
Volume 79,996
3m Avg Volume 152,121
Today’s High 2.95
Today’s Low 2.75
52 Week High 5.80
52 Week Low 2.20
Shares Outstanding (mil) 31.35
Market Capitalization (mil) 165.38
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
13
FY16
6
FY15
0
EPS (USD)
FY18
-0.519
FY17
-0.624
FY16
-1.288
FY15
-1.022
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.69
Price to Sales (TTM)
vs sector
14.52
5.82
Price to Book (MRQ)
vs sector
4.32
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
15.68
16.96
LT Debt to Equity (MRQ)
vs sector
8.36
12.63
Return on Investment (TTM)
vs sector
-68.80
14.32
Return on Equity (TTM)
vs sector
-79.58
16.04

EXECUTIVE LEADERSHIP

Richard Williams
Independent Chairman of the Board, Since 2014
Salary: $540,000.00
Bonus: --
Dennis Carlo
President, Chief Executive Officer, Director, Since 2009
Salary: $393,750.00
Bonus: $160,000.00
Robert Hopkins
Chief Financial Officer, Vice President - Finance, Since 2009
Salary: $177,750.00
Bonus: $45,000.00
David Marguglio
Senior Vice President - Corporate Development, Director, Since 2010
Salary: $197,250.00
Bonus: $65,000.00
Karen Daniels
Vice President - Operations, Since 2009
Salary: $225,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11682 El Camino Real Ste 300
SAN DIEGO   CA   92130-2092

Phone: +1858.9972400

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

SPONSORED STORIES